Weintraub David, Yen Chun-Po, Xu Zhiyuan, Savage Jesse, Williams Brian, Sheehan Jason
Department of Neurological Surgery, University of Virginia Health System, Charlottesville, VA 22908, USA.
J Neurosurg Pediatr. 2012 Dec;10(6):471-7. doi: 10.3171/2012.9.PEDS12257. Epub 2012 Oct 12.
While some low-grade pediatric gliomas may be cured with resection, many patients harbor tumors that cannot be completely resected safely, are difficult to access via an open surgical approach, or recur. Gamma Knife surgery may be beneficial in the treatment of these tumors.
The authors reviewed a consecutive series of 24 pediatric patients treated at the authors' institution between 1989 and 2011. All patients harbored tumors that were either surgically inaccessible or had evidence of residual or recurrent growth after resection. Progression-free survival was evaluated and correlated with clinical variables. Additional outcomes evaluated were clinical outcome, imaging response, and overall survival.
Between 1989 and 2011, 13 male and 11 female patients (median age 11 years, range 4-18 years) with gliomas were treated. Tumor pathology was pilocytic astrocytoma (WHO Grade I) in 15 patients (63%), WHO Grade II in 4 (17%), and WHO Grade III in 1 (4%). The tumor pathology was not confirmed in 4 patients (17%). The mean tumor volume at the time of treatment was 2.4 cm(3). Lesions were treated with a median maximum dose of 36 Gy, median of 3 isocenters, and median marginal dose of 15 Gy. The median duration of imaging follow-up was 74 months, and the median duration of clinical follow-up was 144 months. The tumors responded with a median decrease in volume of 71%. At last follow up, a decrease in tumor size of at least 50% was demonstrated in 18 patients (75%) and complete tumor resolution was achieved in 5 (21%). Progression-free survival at last follow-up was achieved in 20 patients (83%). Progression was documented in 4 patients (17%), with 3 patients requiring repeat resection and 1 patient dying. The initial tumor volume was significantly greater in patients with disease progression (mean volume 4.25 vs 2.0 cm(3), p < 0.001). Age, tumor pathology, tumor location, previous radiation, Karnofsky Performance Scale score, symptom duration, and target dosage did not differ significantly between the 2 groups.
Gamma Knife surgery can provide good clinical control of residual or recurrent gliomas in pediatric patients. Worse outcomes in the present series were associated with larger tumor volumes at the time of treatment.
虽然一些低级别儿童胶质瘤可通过手术切除治愈,但许多患者的肿瘤无法安全地完全切除,难以通过开放手术途径触及,或会复发。伽玛刀手术可能对这些肿瘤的治疗有益。
作者回顾了1989年至2011年在作者所在机构接受治疗的24例连续的儿科患者。所有患者的肿瘤要么无法通过手术触及,要么在切除后有残留或复发生长的证据。评估无进展生存期并与临床变量相关联。评估的其他结果包括临床结果、影像反应和总生存期。
1989年至2011年期间,治疗了13例男性和11例女性胶质瘤患者(中位年龄11岁,范围4 - 18岁)。肿瘤病理为毛细胞型星形细胞瘤(世界卫生组织一级)的有15例患者(63%),世界卫生组织二级的有4例(17%),世界卫生组织三级的有1例(4%)。4例患者(17%)的肿瘤病理未得到证实。治疗时肿瘤的平均体积为2.4立方厘米。病灶接受的中位最大剂量为36 Gy,中位等中心数为3个,中位边缘剂量为15 Gy。影像随访的中位持续时间为74个月,临床随访的中位持续时间为144个月。肿瘤反应的体积中位数减少了71%。在最后一次随访时,18例患者(75%)的肿瘤大小至少减少了50%,5例(21%)实现了肿瘤完全消退。最后一次随访时20例患者(83%)实现了无进展生存期。4例患者(17%)有疾病进展记录,其中3例患者需要再次切除,1例患者死亡。疾病进展患者的初始肿瘤体积明显更大(平均体积4.25立方厘米对2.0立方厘米,p < 0.001)。两组之间的年龄、肿瘤病理、肿瘤位置、既往放疗、卡诺夫斯基功能状态评分、症状持续时间和靶剂量无显著差异。
伽玛刀手术可为儿科患者残留或复发的胶质瘤提供良好的临床控制。本系列中较差的结果与治疗时较大的肿瘤体积相关。